Several autoimmune diseases can damage the heart, and they do so in strikingly different ways. Lupus can scar the heart valves and accelerate artery disease decades ahead of schedule. Scleroderma quietly replaces healthy heart muscle with fibrous tissue. Rheumatic fever, triggered by a common strep throat infection, can permanently warp valve leaflets through a case of mistaken identity in the immune system. Giant cell myocarditis, though rare, can destroy heart muscle so fast that without treatment the median survival is roughly three months. The list goes on, and the mechanisms range from autoantibodies attacking heart proteins to inflammatory cells infiltrating the muscle itself.
Systemic Lupus Erythematosus
Lupus is one of the most thoroughly studied autoimmune diseases in terms of cardiac involvement, and it can affect virtually every structure in the heart. Pericarditis, or inflammation of the sac around the heart, is among the most common cardiac manifestations. But the more dangerous complications involve the valves and the coronary arteries.
Libman-Sacks endocarditis is a hallmark of lupus-related heart disease. Small, sterile growths called vegetations form on the heart valves, most often the mitral valve. These are not caused by bacteria but by immune-driven inflammation and clot formation on the valve surface. Patients with these vegetations tend to have longer disease duration, more active disease, and a higher frequency of other serious complications like kidney involvement and hemolytic anemia.1The American Journal of Medicine. Libman-Sacks Endocarditis in Systemic Lupus Erythematosus: Prevalence, Associations, and Evolution In some cases, these vegetations can cause significant valve damage. One case report describes a young man whose first sign of lupus was sudden shortness of breath caused by a ruptured chord on the mitral valve, directly linked to Libman-Sacks endocarditis.2Journal of Clinical Review & Case Reports. Libman-Sacks Endocarditis and Chordae Tendineae Rupture as Sudden Presentation of Systemic Lupus Erythematous
Beyond the valves, lupus drives premature coronary artery disease at an alarming pace. People with lupus develop atherosclerosis earlier and more extensively than the general population.3PubMed. Premature coronary-artery atherosclerosis in systemic lupus erythematosus This is not simply because lupus patients happen to have traditional risk factors like high cholesterol or high blood pressure. The disease itself, through chronic inflammation, adds an independent layer of cardiovascular risk. Premature coronary heart disease has become a major cause of illness and death in lupus patients.4PubMed Central. Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors In young women with lupus, disease duration and decreased bone density have been identified as independent predictors of early coronary artery calcification, hinting at a shared underlying mechanism between bone loss and vascular damage.5PubMed. Premature coronary artery calcification is associated with disease duration and bone mineral density in young female systemic lupus erythematosus patients
Rheumatic Fever and Rheumatic Heart Disease
Rheumatic fever is a classic example of the immune system’s friendly fire hitting the heart. It starts with a group A streptococcal throat infection, the kind of strep throat most people shrug off with a course of antibiotics. In a subset of people, though, the immune response goes off track. Certain proteins on the streptococcal bacteria look remarkably similar to proteins in the heart, brain, and joints. The immune system, having mounted a defense against the bacteria, gets confused and starts attacking the body’s own tissues. This process is called molecular mimicry.6PubMed Central. Rheumatic fever, autoimmunity, and molecular mimicry: the streptococcal connection
The heart damage in rheumatic fever centers on the valves, particularly the mitral valve. Both autoantibodies and T cells that were originally aimed at the strep bacteria cross-react with heart tissue and drive inflammation that leads to scarring and deformity of the valve leaflets over time.7PubMed Central. Molecular Mimicry, Autoimmunity, and Infection: The Cross-Reactive Antigens of Group A Streptococci and their Sequelae Rheumatic heart disease remains one of the leading causes of preventable heart disease worldwide, especially in low- and middle-income countries where access to antibiotics for strep throat is inconsistent.
Giant Cell Myocarditis
Giant cell myocarditis is rare, but its severity earns it a place near the top of any discussion about autoimmune heart disease. It is driven primarily by T cells that infiltrate the heart muscle and, together with large multinucleated inflammatory cells called giant cells, destroy cardiac tissue rapidly. Without immunosuppressive treatment, the median transplant-free survival is about three months.8PubMed Central. Giant cell myocarditis: from immune pathogenesis to contemporary management
People with this condition deteriorate quickly, often presenting with severe heart failure or dangerous arrhythmias. With aggressive immunosuppression using multiple drugs, the picture improves considerably. One study of patients treated with two to four immunosuppressive drugs reported that transplant-free survival was about 69% at one year and 52% at five years. Even so, roughly 60% of survivors experienced sustained ventricular arrhythmias during follow-up.9PubMed. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression So while modern treatment can keep many patients alive and out of transplant, the heart’s electrical system often remains unstable.
Giant cell myocarditis sometimes appears alongside other autoimmune conditions. In one case series of twelve patients, two had established autoimmune diseases: one with Hashimoto’s thyroiditis and another with an orbital inflammatory pseudotumor.10PubMed Central. Clinical Identification and Characteristic Analysis of Giant Cell Myocarditis in 12 Cases But the majority had no prior autoimmune diagnosis, meaning the heart can be the first and only organ targeted.
Systemic Sclerosis
Systemic sclerosis, often called scleroderma, is best known for skin thickening, but the heart is one of its major target organs. Cardiac involvement can show up as myocardial disease, conduction system problems, arrhythmias, or pericardial disease.11PubMed Central. The heart in scleroderma A particularly insidious feature is myocardial fibrosis, the gradual replacement of healthy heart muscle with scar tissue. This can happen in patches or spread diffusely through the muscle.
Cardiac MRI studies have shown that about 30% of scleroderma patients have focal fibrosis in the heart, compared with none in healthy controls. Diffuse fibrosis markers are also significantly elevated. And roughly a quarter of scleroderma patients studied had ventricular arrhythmias on ambulatory monitoring.12Rheumatology. Myocardial fibrosis and arrhythmic burden in systemic sclerosis The tricky part is that this fibrosis can develop silently. A person with scleroderma may have no cardiac symptoms and still have meaningful heart muscle damage that puts them at risk for sudden arrhythmia or progressive heart failure.
Antiphospholipid Syndrome
Antiphospholipid syndrome is an autoimmune clotting disorder in which antibodies target certain proteins involved in blood coagulation. It frequently damages the heart valves. In a long-term follow-up study, mitral valve thickening appeared in about 72% of patients, mitral regurgitation in 68%, and tricuspid regurgitation in 40%. Over a third of patients developed non-bacterial thrombotic endocarditis, which resembles the Libman-Sacks lesions seen in lupus.13PubMed Central. Heart Valve Involvement in Patients with Antiphospholipid Syndrome: A Long-Term Follow-Up Study of a Single Centre
The mechanism is thought to begin when circulating antiphospholipid antibodies interact with cells on the valve surface, triggering local inflammation and small clots. Over time, these deposits warp the valve structure. Mitral regurgitation is the most common result, though the aortic valve can be involved too.14European Journal of Cardio-Thoracic Surgery. Heart valve surgery in patients with the antiphospholipid syndrome: analysis of a series of nine cases Antiphospholipid syndrome often coexists with lupus, so many patients face overlapping cardiac risks from both conditions.
Eosinophilic Granulomatosis With Polyangiitis and Other Vasculitis
Eosinophilic granulomatosis with polyangiitis, formerly known as Churg-Strauss syndrome, is a form of small-vessel vasculitis that has a particularly aggressive relationship with the heart. Cardiac involvement occurs in roughly 15 to 60% of patients, especially those who are ANCA-negative, and any cardiac structure can be affected.15PubMed. Cardiac involvement in Churg-Strauss syndrome Patients can present with myocarditis, heart failure, pericarditis, arrhythmias, inflammation of the coronary arteries, valve problems, or blood clots inside the heart chambers. A meta-analysis of case reports found that the most common presentation was clinical heart failure, occurring in over half the cases, and left ventricular dysfunction was seen in the vast majority of patients who received echocardiography.16PubMed Central. Cardiac Involvement in Eosinophilic Granulomatosis with Polyangiitis: A Meta-Analysis of 62 Case Reports
Takayasu’s arteritis, a large-vessel vasculitis, damages the heart differently. It tends to narrow or block the openings of the coronary arteries where they branch off from the aorta, rather than attacking the smaller vessels downstream. One case report describes a 19-year-old woman who developed crescendo angina from ostial and left main coronary artery stenosis caused by the disease.17PubMed Central. Takayasu’s arteritis with ostial and left main coronary artery stenosis Because Takayasu’s primarily affects young women, coronary artery disease in a patient that age should raise suspicion for vasculitis rather than typical atherosclerosis.
Sjögren’s Syndrome
Sjögren’s syndrome is typically associated with dry eyes and dry mouth, and its cardiac complications tend to fly under the radar. But a review of reported cases found a range of heart problems in these patients. The most common was atrioventricular block, a disruption of the electrical conduction between the upper and lower chambers, accounting for about 39% of reported cardiac manifestations. Autoimmune myocarditis made up about 26%, and pericardial effusion about 19%.18PubMed Central. Cardiac Manifestations of Sjogren’s Syndrome: A Review of Literature These are not trivial findings. Atrioventricular blocks can cause fainting, fatigue, and in complete block can be life-threatening without a pacemaker.
Rheumatoid Arthritis
Rheumatoid arthritis is usually thought of as a joint disease, but it carries well-established cardiovascular risks. Pericarditis is the most recognized cardiac complication. In rare cases, the pericardial effusion can be large and hemorrhagic. One case report details a patient whose first sign of undiagnosed rheumatoid arthritis was a large hemorrhagic pericardial effusion measuring over 2 centimeters in several dimensions.19PubMed Central. Hemorrhagic Pericardial Effusion as the Presenting Symptom of Newly Diagnosed Rheumatoid Arthritis Beyond pericarditis, chronic systemic inflammation in rheumatoid arthritis accelerates atherosclerosis much the way lupus does, increasing the risk of heart attacks and heart failure even when traditional cardiovascular risk factors are controlled.
How the Immune System Damages Heart Tissue
Across these diseases, there are several recurring mechanisms by which the immune system injures the heart. Autoantibodies that target heart muscle proteins can trigger inflammatory cascades that weaken and remodel the heart over time. When autoantibodies bind to heart tissue, the resulting immune response can worsen the shape and function of both ventricles.20PubMed Central. Functional Autoantibodies in Myocardial Diseases T cells can directly invade the heart muscle, as in giant cell myocarditis. Immune complexes can deposit in vessel walls or on valve surfaces, as in lupus and antiphospholipid syndrome. And chronic inflammation from any of these diseases drives fibrosis, the scarring that stiffens the heart and disrupts its electrical system.
An emerging area of research involves the gut microbiome’s influence on autoimmune heart disease. Mouse studies have shown that disrupting the gut’s microbial balance with antibiotics can actually protect against experimental autoimmune myocarditis and fibrotic heart dysfunction. The susceptibility to disease tracked with the presence of specific immune cells in the gut, and inflammatory signals from the gut directed immune cell migration toward the heart.21PubMed. Regulation of autoimmune myocarditis by host responses to the microbiome This is still early-stage research, but it suggests that the road from autoimmunity to heart damage may start farther from the heart than anyone expected.
When Cancer Treatment Triggers Heart Autoimmunity
Immune checkpoint inhibitors, a class of cancer drugs that unleash the immune system to fight tumors, have created an entirely new category of autoimmune heart disease. By removing the brakes on immune activity, these drugs can cause the immune system to attack healthy heart muscle. This form of myocarditis, though uncommon, is dangerous when it occurs.
Research has begun to reveal the mechanism. In mouse models, immune checkpoint inhibitor treatment causes monocytes and T cells to infiltrate the heart and organize into structured immune clusters that researchers have called tertiary T cell niches. These niches act as hubs for T cell activation right inside the heart tissue, and a gene signature associated with them has been found in cardiac tissue from human patients with checkpoint inhibitor myocarditis.22PubMed Central. Cardiac tertiary immune niches drive immune activation in immune checkpoint inhibitor myocarditis Separate research has identified an inflammatory protein called ANGPTL2, produced by heart fibroblasts, that acts as a chemical beacon drawing T cells into the heart during checkpoint inhibitor treatment.23PubMed Central. ANGPTL2 promotes immune checkpoint inhibitor-related murine autoimmune myocarditis Understanding these pathways matters because millions of cancer patients now receive these drugs, and identifying who is at risk for cardiac complications could prevent deaths.
Maternal Autoimmunity and Fetal Heart Block
Autoimmune heart disease does not always affect the person who has the autoimmune condition. In pregnant women with lupus or Sjögren’s syndrome, certain antibodies, specifically anti-Ro/SSA and anti-La/SSB, can cross the placenta and damage the developing fetal heart. This causes autoimmune congenital heart block, in which the electrical conduction system of the fetal heart is disrupted.24PubMed Central. Autoimmune Congenital Heart Block: A Review of Biomarkers and Management of Pregnancy
Studies have confirmed the link by examining mothers of affected infants. In one study, all twenty mothers of permanently affected babies had antibodies targeting components of the SSA/Ro-SSB/La system, and those same target proteins were found abundantly in fetal cardiac tissue during the vulnerable window of 18 to 24 weeks of pregnancy.25PubMed Central. Acquired congenital heart block. Pattern of maternal antibody response to biochemically defined antigens of the SSA/Ro-SSB/La system in neonatal lupus Some affected babies require a pacemaker at birth or shortly after. This is one of the few situations where an autoimmune disease in one person directly causes structural heart disease in another.
Detecting Cardiac Involvement Early
One of the challenges with autoimmune heart disease is that damage can accumulate before symptoms appear. Cardiac MRI has emerged as the most valuable imaging tool for catching early involvement. It can detect inflammation, swelling, and fibrosis in the heart muscle with a level of detail that standard echocardiography often misses. The presence of late gadolinium enhancement, a pattern on cardiac MRI that highlights scarred tissue, has been consistently linked to worse cardiovascular outcomes.26PubMed Central. Cardiac MRI in Autoimmune Diseases: Where Are We Now? Cardiac MRI is now considered the gold standard for evaluating heart structure and function in autoimmune rheumatic diseases, including tissue characterization that can distinguish between active inflammation and established scar.27PubMed Central. The role of comprehensive stress cardiac MRI in autoimmune rheumatic disease: A review
For lupus in particular, there has historically been a large gap between what autopsy studies reveal and what gets diagnosed during a patient’s lifetime. Cardiac MRI may help close that gap. The practical takeaway for anyone with a systemic autoimmune disease is that the absence of chest pain or shortness of breath does not guarantee a healthy heart. Screening conversations with your rheumatologist or cardiologist about imaging are worth having, especially if the disease has been active for several years.
Treatment Tradeoffs
Treating autoimmune heart disease means walking a tightrope. The drugs that suppress the immune system enough to stop the attack on the heart can themselves cause cardiovascular damage. Cyclophosphamide, used in severe lupus and vasculitis, has direct toxic effects on heart muscle and can cause heart failure. Prednisone, the workhorse steroid in autoimmune care, raises blood pressure and cholesterol over time, which accelerates the very coronary artery disease that lupus and other conditions already promote.28ScienceDirect. The Effects of Immunosuppressive and Cytotoxic Drugs on the Heart So physicians constantly balance the risk of undertreating the autoimmune disease against the risk of the treatment itself worsening cardiovascular health.
In giant cell myocarditis, this balance is especially stark. Without aggressive immunosuppression, the disease is nearly always fatal within months. With it, most patients survive, but many remain vulnerable to life-threatening arrhythmias and may eventually need an implantable defibrillator or a heart transplant.
When Transplant Becomes the Only Option
For patients whose hearts are destroyed by autoimmune disease, transplantation is sometimes the last resort. Heart transplant outcomes in conditions like cardiac sarcoidosis and giant cell myocarditis have been studied in meta-analyses and are comparable to outcomes in patients transplanted for other causes of heart failure. Disease recurrence after transplant occurs in about 5% of sarcoidosis cases and 8% of giant cell myocarditis cases.29PubMed Central. Short- and long-term outcomes after heart transplantation in cardiac sarcoidosis and giant-cell myocarditis: a systematic review and meta-analysis
Lupus presents a different story. Many transplant centers have historically considered it a contraindication because of the risk that the immune disease will attack the new heart too. But accumulating case evidence suggests that carefully selected lupus patients can do well after transplant.30Heart & Lung. Heart transplantation in systemic lupus erythematosus: A case report and meta-analysis The field is slowly moving toward a more case-by-case approach rather than an automatic refusal.
Why Women Are Disproportionately Affected
Most of the diseases described here are far more common in women than in men. Lupus, Sjögren’s syndrome, scleroderma, and antiphospholipid syndrome all skew heavily female. The reasons are layered. Sex hormones, particularly estrogen, influence immune regulation in ways that tend to push the system toward stronger and sometimes misdirected responses. The X chromosome carries a high density of immune-related genes, and having two copies of it provides more raw material for immune dysregulation. Epigenetic modifications driven by estrogen and the environment further shape which genes get turned on or off in immune cells.31PubMed Central. Mechanisms underlying sex differences in autoimmunity
This sex disparity has practical consequences for cardiac screening. Young women are already less likely to have their cardiovascular symptoms taken seriously by healthcare providers. When that young woman also has lupus or another autoimmune disease, the risk of dismissing cardiac symptoms as anxiety or musculoskeletal pain is compounded. Awareness that autoimmune disease adds independent cardiac risk, starting decades earlier than typical heart disease, is critical for both patients and the clinicians who see them.